Back to top
more

Relay Therapeutics (RLAY)

(Delayed Data from NSDQ)

$3.53 USD

3.53
1,369,707

0.00 (0.00%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $3.53 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 127.27% and 155.31%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -3.85% and 69.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -11.43% and 42.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 94.78%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 94.8% in Relay Therapeutics, Inc. (RLAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of 21.13% and 66.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to Decline

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Lannett (LCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lannett (LCI) delivered earnings and revenue surprises of 17.07% and 10.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Esperion Therapeutics (ESPR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.90% and 4.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?